BACKGROUND: Tb, in combination with PSMA-617 for imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer, was demonstrated in a preclinical setting and in a patient with metastatic castration-resistant prostate cancer (mCRPC). RESULTS: Ga-PSMA-11 PET/CT acquired 45 min p.i. CONCLUSIONS: Tb, which has promising decay characteristics for an effective treatment of mCRPC patients.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: